[BREAKING] Hemerion obtains the FDA clearance for its next US clinical trial


Press Release-October 28, 2021

Hemerion and Mount Sinai Hospital awarded the Galien MedStartup Prize for “Best Collaboration in the MedTech and Digital Health” category

Hemerion and Mount Sinai Health System (NYC) are collaborating to launch an ambitious clinical trial in 2022. This collaboration has won the “Best Collaboration in the MedTech and Digital Health” award of the Galien Medstartup Prize: an international recognition that perfectly kickstarts the Hemerion development in the USA.

The Galien Medstartup fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Since 2013, it supports the international development of the most promising French startups, selected by a world-renowned panel, and connects them with leading American businesses.
Hemerion and Mount Sinai were competing in the “Best Collaboration in the MedTech and Digital Health” category, a prize that rewards excellence for an academic-medtech project.

An international recognition for an ambitious clinical program to fight glioblastoma

Encompassing the Icahn School of Medicine and eight hospital campuses in the New York metropolitan area, Mount Sinai is internationally acclaimed for its excellence in research, patient care, and education across a range of specialties, including neurosurgery.
The Hemerion / Mount Sinai collaboration aims to clinically evaluate the Hemerion technology efficacy against glioblastoma, the most common and aggressive brain cancer.
Hemerion technology associates drugs with innovative laser treatments to selectively kill cancer cells without harming healthy tissue. Used during surgery, before any adjuvant treatment or drug can be delivered, Hemerion technology has the potential to significantly improve both survival and quality of life in patients.
The award recognizes the clinical project developed by Hemerion and Mount Sinai as a genuine breakthrough in the upfront management of newly diagnosed glioblastoma.

A springboard to speed up Hemerion’s clinical and industrial projects in the USA

The Galien Award recognizes the Hemerion / Mount Sinai collaboration as one of the most innovative and promising North American-French projects in the healthcare sector.
It is an important milestone for Hemerion that will speed up its development in the USA. Within the frame of the Galien Innovation Week, the Hemerion team already met with a dozen of prominent American neurosurgery leaders to further expand its clinical trial program.

About Hemerion Therapeutics


Hemerion was created in 2020, after more than 10 years of academic research in an Inserm Lab at the University of Lille and the Lille University Hospital. The company gathers complementary profiles to develop innovative therapeutic solutions. Its first breakthrough technology addresses glioblastoma as a complement to neurosurgery. Its efficacy is currently being evaluated in clinical trials.